Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity by Kwok, Hang Fai et al.
RESEARCH Open Access
Antibody targeting of Cathepsin S induces
antibody-dependent cellular cytotoxicity
Hang Fai Kwok
1*, Richard J Buick
1*, Diana Kuehn
1, Julie A Gormley
1, Declan Doherty
1, Thomas J Jaquin
1,
Angela McClurg
1, Claire Ward
1, Teresa Byrne
1, Jacob Jaworski
1, Ka Lai Leung
1, Philip Snoddy
1, Christine McAnally
1,
Roberta E Burden
1,2, Breena Gray
1, Jenny Lowry
1, Isabelle Sermadiras
1, Natalia Gruszka
1, Nigel Courtenay-Luck
1,
Adrien Kissenpfennig
3, Christopher J Scott
2, James A Johnston
1,3 and Shane A Olwill
1
Abstract
Background: Proteolytic enzymes have been implicated in driving tumor progression by means of their cancer cell
microenvironment activity where they promote proliferation, differentiation, apoptosis, migration, and invasion.
Therapeutic strategies have focused on attenuating their activity using small molecule inhibitors, but the
association of proteases with the cell surface during cancer progression opens up the possibility of targeting these
using antibody dependent cellular cytotoxicity (ADCC). Cathepsin S is a lysosomal cysteine protease that promotes
the growth and invasion of tumour and endothelial cells during cancer progression. Our analysis of colorectal
cancer patient biopsies shows that cathepsin S associates with the cell membrane indicating a potential for ADCC
targeting.
Results: Here we report the cell surface characterization of cathepsin S and the development of a humanized
antibody (Fsn0503h) with immune effector function and a stable in vivo half-life of 274 hours. Cathepsin S is
expressed on the surface of tumor cells representative of colorectal and pancreatic cancer (23%-79% positive
expression). Furthermore the binding of Fsn0503h to surface associated cathepsin S results in natural killer (NK) cell
targeted tumor killing. In a colorectal cancer model Fsn0503h elicits a 22% cytotoxic effect.
Conclusions: This data highlights the potential to target cell surface associated enzymes, such as cathepsin S, as
therapeutic targets using antibodies capable of elicitingADCC in tumor cells.
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Background
Proteases regulate a number of pathways relevant to can-
cer biology, including proliferation, differentiation, apop-
tosis, migration, and invasion [1,2]. In the last decade, it
has become increasingly evident that tumor cells create a
pericellular microenvironment where molecules such as
metalloproteinases, cysteine proteases and serine pro-
teases interact to form a pro-tumorigenic proteolytic net-
work [2,3]. Indeed the establishment of a causal
relationship between enhanced activity or expression of
proteases and tumor progression (e.g. through extracellu-
lar matrix remodelling) has promoted the development
of many small molecule inhibitors as anticancer thera-
peutics. However clinical trials with many of these agents
have been disappointing due to their off target effects
coupled with poor bioavailability, leading drug developers
to consider the use of biologic inhibitors (antibodies or
peptides) [1,4,5]. There is an increasing body of evidence
suggesting that proteases involved in cancer microenvir-
onment which are normally found within intracellular
compartments often relocate during tumor progression,
resulting in secretion and association with binding part-
ners on the tumor cell surface [6-9].
Cathepsin S is one of a family of eleven lysosome
cysteine proteases normally restricted to the lysosomes of
professional antigen presenting cells where it mediates
cleavage of the invariant chain (li) from MHC class II
complexes prior to antigen loading for presentation
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any medium, provided the original work is properly cited.[10-12]. In cancer, cathepsin S is translocated from its
normal intracellular lysosomal compartment into the
extracellular milieu [13,14]. Reports have shown that
cathepsin S is stable at neutral pH and is potently elastin-
and collagenolytic, promoting extracellular matrix remo-
delling, tumor growth and invasion in the tumor micro-
environment [15,16]. Enhanced cathepsin S expression
and activity have been detected in several human cancers
(glioma, breast, prostate, colorectal and pancreatic) with
in vivo mouse models supporting its role in tumorigen-
esis [17-21]. The association of cathepsin S with colorec-
tal cancer progression has been recently highlighted
where it was shown to be a prognostic indicator [22]. A
number of groups have studied the mechanistic role of
cathepsin S in cancer using in vitro and in vivo models
[18,21].
The potential of cathepsin S as a novel cancer target
amenable to antibody mediated therapy has been exam-
ined using a murine anti-cathepsin S monoclonal antibody
(Fsn0503) which is capable of blocking tumor cell inva-
sion, endothelial tube formation and microvascular
sprouting during angiogenesis [23,24]. While previous
reports had suggested that cathepsin S is found either in
the lysosomal lumen or secreted into the ECM, our analy-
sis of colorectal cancer patient biopsies and cancer cell
lines show that it is also associated with the cell membrane
indicating a potential for antibody dependant cellular cyto-
toxicity (ADCC) targeting.
ADCC relies on a mechanism of Fc effector domain
recruitment of immune cells (e.g. Natural Killer) to
tumor cells with surface bound antibody. Advances in
recombinant antibody engineering facilitate the introduc-
tion of immune effector function for those antibodies
which target cell surface antigens [25,26].
In the present study, we show that cathepsin S is on the
surface of tumour cells and that this localization can be
exploited with a fully human IgG1 version of Fsn0503
(Fsn0503h) to induce ADCC, demonstrating the clinical
potential of the engineered cathepsin S specific human
antibody Fsn0503h.
Results
Cathepsin S is expressed on the surface of Colorectal
Cancer (CRC) tumor cells
The prevalence of cathepsin S (>95% patients) in CRC
was recently demonstrated in a large-scale IHC study
spanning three cohorts of patient samples (n = 561) [22].
In addition to the relationship of Cathepsin S levels with
the disease, a distinct polarization to either the basal or
apical epithelial membrane was also observed in 40% of
cases, as shown in Figure 1, which is suggestive of cell
surface localization and potential secretion of the pro-
tease into the tumor microenvironment.
We next examined the expression of cathepsin S on a
panel of cancer cell lines (Colo205, LoVo, BxPC-3, Aspc-1
and Panc-1) by western blot. A clear band was observed at
approximately 28 kDa for all the cell lines, except Panc-1
which was found to be cathepsin S negative (included as a
negative control), (Figure 2). The results confirmed
expression of the protease in Colo205, LoVo, BxPC-3 an
Aspc-1 cell lines and we also demonstrated its secretion
into the growth media (data not shown). As we postulated
that cathepsin S is translocated from its intracellular com-
partment to associate with the tumor cell surface prior to
secretion, we examined the cell surface expression of
cathepsin S across the panel of cell lines by flow cytom-
tery. A significant amount of cell surface cathepsin S was
detected in our panel of cancer cell lines. A higher percen-
tage of LoVo and BxPC3 cells stained positive for surface
cathepsin S (79.6% and 74.4% respectively) compared to
the Colo205 and Aspc-1 cells (22.3% and 29.7% respec-
tively) (Figure 3A). To perform a comparative quantifica-
tion of cell surface associated cathepsin S across the cell
lines we used the QuantiBRITE PE beads flow cytometry
system. Using a 1:1 target to antibody ratio we observed a
similar level of cathepsin S expression on all cell lines. The
results demonstrated that there was between 1765-6209
antibodies bound per cell (ABC) indicating a similar range
of cathepsin S antigen density expressed on each cancer
type assessed (Figure 3B).
To further assess the translocation of cathepsin S from
intracellular compartments to the cell surface, cancer cell
lines (Colo205, LoVo, BxPC-3 and Aspc-1) were analysed
by confocal microscopy. In all cell lines, intense cathepsin
S staining co-localizes with actin at focal points on the cell
membrane mirroring the expression pattern observed in
patient biopsy samples (Figure 3C & 3D). This suggests a
concentrated localization of cathepsin S at specific areas of
the cell surface. This expression pattern of localised
regions of high antigen density is observed in a subset of
cells potentially indicating tight regulation of surface
expression. In some cases, cathepsin S expression can be
observed in protrusions of the cell membrane, potentially
areas of exocytosis.
Humanization and characterization of Fsn0503
To facilitate future clinical development the murine anti-
body, Fsn0503, was humanized using recombinant anti-
body engineering. The Fsn0503h variable domain
sequences are shown in alignment with the parental
Fsn0503 murine variable domain sequences in Figure 4A
with all constant determining regions (CDR’s) conserved.
The constant domains of the antibody (isotype) were
selected as human IgG1 in order to confer ADCC activity
to the human version of the antibody. A stable pool of
NSO1 cells expressing Fsn0503h was selected using the
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Page 2 of 10DHFR inhibitor MTX (200 nM). A single high yield cell
line was then isolated by limiting dilution for downstream
production. Purified antibodies were analysed by SDS-
PAGE (Figure 4B) and tested in a competition ELISA for
binding to their target antigen, cathepsin S, against bioti-
nylated murine anti-cathepsin S (Figure 4C). The
Fsn0503h heavy chain and light chain can be clearly seen
on the SDS-PAGE gel at 50-and 32-kDa respectively. As
expected, they are slightly different in size to their murine
Fsn0503 equivalent chains due to the differing size of the
constant domains. The competition ELISA (Figure 4C)
demonstrates that the Fsn0503h antibody displays a simi-
lar binding profile to the parental Fsn0503 antibody,
indicating no change in affinity during the humanization
process which is further supported by similar affinities and
off rates when assessed by biacore and comparable in vitro
efficacy (data not shown). In order to evaluate the poten-
tial serum half-life of Fsn0503h and blood clearance rates
a pharmacokinetic study was performed in SD rats. The
PK profile for each individual animal was analysed as well
as the analysis of pooled serum samples for each time
point. Both methods of analysis gave similar PK profiles.
Analysis of data using a bi-exponential model gives an
initial half-life value of 14.8 hours with a terminal half-life
of 274 hours (Figure 4D). Taken together the results
demonstrate the successful engineering of Fsn0503h into
(C)
(B)
(A)
Figure 1 Representative images (A, B and C): Polarised cathepsin S expression patterns in colorectal cancer patient biopsies. Cathepsin S-
specific staining is brown (indicated with arrow heads) and nuclear counterstaining is blue. (Scale bars - 100 μm).
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netic properties.
ADCC of Fsn0503h in colon and pancreatic carcinoma cell
line
ADCC relies on the mechanism of cell-mediated immu-
nity whereby an effector cell actively lyses a tumor cell
which has been bound by a specific antibody. To deter-
mine the ADCC potential of our humanized antibody,
Fsn0503h, we evaluated its efficacy to kill LoVo and
Aspc-1 cancer cell lines by ADCC using an LDH release
assay. Fsn0503h was capable of mediating cytotoxic kill-
ing of target cancer cells in a dose-dependent manner
(from 883.75 nM to 6670 nM) when assayed with iso-
lated human donor PBMCs. The dose-dependent cyto-
toxic effect of Fsn0503h on LoVo and Aspc-1 cell lines
had a maximal efficacy of approximately 22% and 13%
respectively (Figure 5A). In order to demonstrate which
Fc receptor is engaged in PBMC-mediated killing by
Fsn0503h the ADCC experiments were also performed
in the presence of a specific FcgRIII blocking antibody
(CD16). Killing by isolated PBMCs was effectively neu-
tralised by the presence of CD16 antibody (6670 nM)
demonstrating the required involvement of FcgRIII on
effector cells (e.g. natural killer (NK)cells) in Fsn0503h
dependent ADCC (Figure 5B). The cathepsin S-negative
cell line Panc-1 was also used as a control to show the
ADCC efficacy of Fsn0503h is due to the specific bind-
ing of cathepsin S.
Discussion
Here we demonstrate expression of cathepsin S on the
surface of pancreatic and colon carcinoma cells. In addi-
tion, we reveal how cell surface associated cathepsin S
can be targeted to mediate ADCC by a fully humanized
anti-cathepsin S antibody, Fsn0503h. To the best of our
knowledge this is the first example of a protease or sur-
face enzyme being targeted to elicit ADCC.
Cathepsin S is a cysteine protease that plays a key role
in invasion, angiogenesis and metastasis during tumor
progression [21,27-29]. In normal conditions, cathepsin
S has limited tissue distribution and is found primarily
in lysosomal compartments of professional antigen pre-
senting cells; however it is up-regulated and secreted
into the microenvironment during tumor development
[11,21]. Based on our findings, we postulate that during
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Figure 2 Western blot analysis of cathepsin S on different cancer cell lines: Colo205, LoVo, BxPC-3, Aspc-1 and Panc-1. Density of the
bands (Cathepsin S/g-Tubulin ratio) is represented as % of relative optical density units.
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associates with the tumour cell surface. Cathepsin B has
previously been shown to localize to the cell surface
[30]. Under normal circumstances cathepsin B, a house-
keeping enzyme, is located in perinuclear lysosomes but
in cancer it is secreted and relocalized to the plasma
membrane. While the exact mechanisms underlying
intracellular enzyme shuttling of cathepsins remain to
be elucidated it is thought that mannose-6-phosphate
receptors (MPR) may play a role albeit via discrete path-
ways for individual family members [31]. Under certain
conditions, including reduced pH, lysosomes may fuse
with the plasma membrane, thus becoming secretory
organelles, which facilitate association with the cell sur-
face [32]. This membrane association is supported by
our flow cytometry findings which show on average 23-
79% of Colo205, LoVo, BxPC-3 and ASPC1 cells express
cell surface cathepsin S. IHC analysis of patient biopsies
further demonstrate cell surface localization of cathepsin
S where staining is characterized by a distinct polariza-
tion to either the basal or apical epithelial membrane.
Confocal analysis of cancer cell line models also support
this association as cathepsin S was observed to localize
to the cell surface membrane with intense staining
restricted to specific regions. A pattern of regional
expression has also been reported for other proteases
involved in tumorigenesis which have been shown to
congregate in caveolae. Caveolae have multiple proteoly-
tic factors (e.g. cathepsins, annexins, uPA, MMP’s)
which represent concentrated membrane sub-domains
(protease pools) that facilitate organized cell surface pro-
teolysis [33]. As well as facilitating co-operation between
different proteases the concentration of cathepsin S in
focal micro-domains, results in regions of high antigen
density, which can beused to induce ADCC.
As discussed above, Fsn0503 is a murine IgG1 anti-
body, shown to have anti-tumor efficacy in xenograft
models through inhibition of cathepsin S mature protein.
Cancer cell line Antibody Bound per Cell (ABC)
Colo205 1765.10
LoVo 2837.59
BxPC-3 3735.75
Aspc-1 6209.08
(A)
(B)
(C) (i) CoLo205  (D)
Figure 3 Cathepsin S surface expression quantification on cancer cell lines. (A) Cathepsin S surface expression on Colo205, LoVo, Bx-PC3,
Aspc-1 and Panc-1 by flow cytometry. (B) QuantiBRITE PE beads fluorescence quantification of cathepsin S expressed on the surface of cathepsin
S-positive cell lines (Colo205, LoVo, BxPC-3 and Aspc-1). (C, D) Confocal microscope images of LoVo (C) and Aspc-1 (D) cell lines show human
tumor expression of cathepsin S on the cell surface (Colo205, BxPC-3 and Panc-1 shown in supplementary figures): Left panels show isotype
control while right panels show cathepsin S specific antibody (green) binding to the cell surface, indicated with arrow heads.
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Page 5 of 10The murine IgG1 isotype has negligible ADCC potential
and has the added drawback that if administered to
patients undergoing immunotherapy may result in a
strong human anti-mouse antibody (HAMA) response
with rapid clearance. To make the antibody suitable for
clinical utility we have developed a fully human version.
The majority of therapeutic antibodies are human IgG1
isotypes (e.g. Herceptin and Cetumximab), particularly in
oncology as it facilitates the introduction of additional
effector function. IgG1 allows engagement of immune
effector cells through binding of Fc receptors (FcgR)
expressed on NK cells, macrophages and polymorpho-
nuclear leukocytes with the NK population identified as
the principal instigator of ADCC [34-36]. IgG4 isotype
antibodies such as natalizumab (Tysabri) are more com-
monly used in applications where cell killing is not the
objective, such as multiple sclerosis or rheumatoid arthri-
tis. Based on our findings that cathepsin S is associated to
the surface of the tumour cells we engineered a human
antibody with ADCC functionality. Through the use of a
specific human IgG1 framework the recombinant anti-
body, Fsn0503h with an in vivo half-life of approximately
11.4 days (274 hours), has the potential to recruit NK
cells via the FcgRIIIa (CD16a)and to actively kill tumor
cells in patients [35]. In order to evaluate the ADCC
effector function of Fsn0503h we performed ex vivo activ-
ity assays using healthy donor peripheral blood mono-
nuclear cells as it is difficult to obtain meaningful data
from current in vivo murine models. Human IgG1 anti-
bodies have much reduced ADCC activity in mouse
xenograft models due to differing species immune cell
recognition patterns [37,38]. We chose to assess the
effector function of our human antibody using a well
characterized LDH release assay and demonstrated that
Fsn0503h is capable of eliciting greater than 20% specific
cytotoxic cell kill in the LoVo colorectal cancer model.
Furthermore with the use of an anti-CD16 neutralising
antibody we have shown that the ADCC functionality of
Fsn0503h works through the recruitment of CD16 posi-
tive immune cells such as human NK cells to induce
tumour cell death.
Currently twenty-two therapeutic antibodies have been
approved by the US Food and Drug Administration
(FDA), at least eleven of which are for the treatment of
cancer [39,40]. While antibodies such as rituximab have
proven very efficacious for the treatment of leukaemia the
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Figure 4 (A) Alignment of Fsn0503 variable domains and designed Fsn0503h human variable domains. Amino acid residues mutated
from the murine sequence are highlighted. CDRs are boxed. (B) 4-20% SDS gel analysis showed the highly purified cathepsin S antibodies: Lane
1 – Fsn0503h; Lane 2 – Fsn0503; Lane 3 - Human isotype antibody control; Lane 4 – SeeBlue plus marker. (C) Compeptitive immunoreactivity
profile: Fsn0503h & Fsn0503 was allowed to compete with a biotin-labeled Fsn0503 (120 nM) for binding to recombinant Fsn0503 mature
antigen (40 nM). (D) Pharmacokinetic analysis of Fsn0503h in rats. Following a single i.v. administration of Fsn0503h using a bi-exponential
model (linear scale), it showed that the initial half-life value of Fsn0503h was 14.8 hours with a terminal half-life of 274 hours (approximately 11.4
days).
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Page 6 of 10clinical impact of drugs such as cetuximab (anti-EGFR)
and bevacizumab (anti- VEGF) in solid tumors has, how-
ever, been less dramatic. A reason for this may be the lim-
ited penetration of antibodies into the tumor but also an
under appreciation of potential effector function. To
improve upon existing therapies recombinant antibodies
which have been optimized to elicit immune effector func-
tion (e.g. ADCC) are now emerging as a major new class
of drugs [40]. With this in mind it is important to assess
all potential mechanisms of killing for any novel drug. The
identification of novel cancer targets will help to broaden
the number of patients for which antibody-based immu-
notherapy may be effective. The demonstration of cathe-
psin S targeted ADCC efficacy opens up the possibility of
targeting other enzymes (such as MMP’s, ADAMs) in a
similar way. Antibodies such as Fsn0503h, combining
immune effector function with the ability to specifically
block protease activity as demonstrated in our previous
published data [23], may have significant clinical utilityfor
the treatment of cancer.
Conclusions
In summary, we demonstrate expression of cathepsin S
on the surface of pancreatic and colon carcinoma cells
and reveal how cell surface associated cathepsin S can
be targeted to mediate ADCC by a fully humanized
anti-cathepsin S antibody, Fsn0503h. This is the first
example of a protease or surface enzyme being targeted
to elicit ADCC. This data highlights the potential to tar-
get cell surface associated enzymes as therapeutic targets
using antibodies capable of eliciting ADCC in tumor
cells.
Materials and Methods
Cancer cell lines
The human cancer cell lines (Colo205, LoVo, BxPC-3,
Panc-1 and Aspc-1) were purchased from American
Type Culture Collection (ATCC, Rockville, MD). The
colon carcinoma cell lines, Colo205 and LoVo, were cul-
tured in RPMI 1640 medium (Sigma Aldrich, UK) and F-
12K medium (Invitrogen, UK) respectively, supplemented
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Figure 5 Fsn0503h specifically induces antibody-dependent cellular cytotoxic (ADCC) killing of tumor cells through a CD16 dependent
mechanism. (A, B) The dose dependent ADCC activity of Fsn0503h in (A) LoVo and (B) Aspc-1 cell lines. LoVo/Aspc-1 cells were incubated with
human peripheral blood mononuclear cells (PBMCs) obtained from healthy donors which were stimulated with IL-2 (100 U/mL) at an E/T ratio of
40/1 in the presence of various concentrations of Fsn0503h. (C) ADCC activity of Fsn0503h (6670 nM) in LoVo and Aspc-1 cell line was blocked
in the presence of CD16 neutralising antibody (6670 nM). The cathepsin S-negative cell line (Panc-1) was used as a negative control. *P < 0.01
(paired t-test) for Fsn0503h versus Fsn0503h+CD16 antibody.
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Page 7 of 10with 10% foetal calf serum (FCS) (PAA, Laboratories,
Somerset, UK) and L-glutamine (10 nmol/L) (Invitrogen,
UK). BxPC-3, Aspc-1 and Panc-1 (pancreatic carcinoma)
were cultured in RPMI 1640 medium (Invitrogen, UK)
supplemented with 10% foetal calf serum (FCS) (PAA,
Laboratories, Somerset, UK) and L-glutamine (10 nmol/
L) (Invitrogen, UK). All cultures were maintained in a
humidified environment at 37°C with 5% CO2.
Immunohistochemistry (IHC) staining
Tissue microarray sections, containing biopsy cores taken
from colorectal cancer patient specimens, were stained
for cathepsin S as previously described [21] using an
automated IHC platform (Bond Max™, Leica Microsys-
tems, Newcastle, UK). Mouse anti-cathepsin S antibody
Fsn0503 (Fusion Antibodies Ltd.) was used at 4 ug/mL.
A polymer-based detection system (Refine cat#DS9800)
was used with 3’,3-Diaminobenzidine (DAB) as the
chromogen.
Western blotting and Flow cytometry
To prepare whole cell lysates of Colo205, LoVo, BxPC-3,
Aspc-1 and Panc-1, cell pellets were washed in PBS and
lysed using standard RIPA buffer supplemented with a
Calbiochem
® protease inhibitor cocktail set III (1:50 dilu-
tion of lysis buffer) (Merck Chemicals Ltd., UK) as pre-
viously described [22]. Samples were incubated for 30
minutes on ice prior to a 20 minute centrifugation at
13,000 rpm. Protein concentration was determined by
BCA assay (Thermo Scientific, UK). Denatured samples
were analysed by SDS-PAGE on 12% (w/v) polyacrylamide
gels. Gels were transferred by semi-dry blotting onto nitro-
cellulose membrane, blocked with 3% dried milk before
probing with 0.4 μg mouse anti-Cathepsin S antibody in
15 mL PBS overnight 4°C. Following washes in phosphate-
buffered saline tween (PBS-T), membranes were probed
with goat anti-mouse-HRP (1:3000) (Bio-Rad Laboratories
Ltd., UK) for 1 hour at room temperature. After a series of
further washes with PBS-T, membranes were developed
using Chemiluminescent Substrate (West Pico Chemilu-
minescent Substrate, Pierce) for 5 minutes.
The surface expression of cathepsin S on Colo205,
LoVo, BxPC-3, Aspc-1 and Panc-1 cell lines was examined
and quantified by flow cytometry. Briefly, cells (0.5 × 10
6)
were washed with cold Cell Wash (BD Biosciences, UK)
and incubated with 0.5μg of polyclonal goat anti-cathepsin
S antibody (R&D Systems, UK) in PBS for 1.5 hour on ice.
The cells were then washed with cold Cell Wash and incu-
bated with R-PE-conjugated donkey anti-goat antibody
(1:50) (Abcam, UK) in PBS for 1 hour on ice. The cells
were washed with cold PBS and stored at 4°C in the dark
prior to analysis on the FACSCanto (BD Biosciences, UK).
Target quantification was performed using QuantiBRITE
PE beads (BD Biosciences, UK). Briefly, QuantiBRITE PE
beads were run on the BD FACSCanto using the same
parameters for fluorescence as used for the analysis of the
cell lines. Geometric means were displayed in the statistic
view (BD FACS Diva Software v6.1) and the calculation of
Antibody Bound per Cell (ABC) values was carried out
according to the manufacturer’s protocol.
Confocal microscopy
To assess localized cathepsin S expression Colo205, LoVo,
BxPC-3, Aspc-1 and Panc-1 cells were grown on cover-
slips at 20,0000 cells/well in a humidified environment at
37°C with 5% CO2 overnight. The cells were then rinsed
with Cell Wash (BD Biosciences, UK) and fixed with 4%
paraformaldehyde (PFA) for 15 minutes at room tempera-
ture. After fixing, the cells were washed with PBS and
non-specific sites were quenched with a blocking buffer
(PBS containing 10% goat serum) for 2 hours. The cells
were then incubated with 32 μg of mouse anti-cathepsin S
antibody Fsn0503 or mouse isotype antibody control
(Fusion Antibodies Ltd., UK) for 1 hour at 37°C. After
extensive rinsing with PBS, the cells were incubated with
10 μg/mL goat anti-mouse AlexFlour 488-conjugated sec-
ondary antibody (Invitrogen, UK) in blocking buffer for 1
hour in the dark. Labelling of actin filaments was per-
formed with Molecular Probes
® rhodamine phalloidin
(1:150) (Invitrogen, UK). After extensive washing, the cov-
erslips were mounted upside-down on glass microscope
slides using Vectashield
® media (Vector Laboratories Inc.,
Burlingame, CA, USA) and viewed on laser confocal
microscope.
Humanization of the murine antibody
mRNA was extracted from 10
6 cells of Fsn0503 using
STAT60 reagent. RT-PCR was performed using an oligo
(dT) primer and reverse transcriptase, followed by PCR
with murine specific IgG degenerate primers. The PCR
products were cloned into the pCR2.1 vector (Invitrogen)
for sequencing analysis. The vector was transformed into
TOP10 cells and positive clones identified by PCR. The
plasmid clones were mini-prepped and sequenced by the
dideoxy-chain termination method on an ABI 3130xl
genetic analyser. A consensus sequence for the light chain
and heavy chain variable domains was determined from a
minimum of 5 clones.
A Composite Human Antibody™ version of the
Fsn0503 antibody, Fsn0503h, was designed from multiple
human antibody sequences, with CDRs (complementarity
Determining Regions) identified using Kabat and Chothia
definitions (REF). The composite sequence was screened
for T cell epitopes binding to human MHC Class II alleles
(Antitope). The Fsn0503h VH and VL sequences were
synthetically constructed a n dc l o n e di n t oa ne x p r e s s i o n
vector containing human IgG1 isotype constant domains.
Human IgG1 isotype was selected as the optimum isotype
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transfected via electroporation with both heavy chain and
light chain expression vectors. Electroporated cells were
distributed into 5 × 96 well plates and selected with 200
nM MTX (methotrexate). Wells containing methotrexate
resistant colonies were sampled and tested for IgG expres-
sion levels, and the best expressing line was selected and
frozen down (Antitope). Fsn0503h was then further
selected by two rounds of limiting dilution in 96 well
plates in the presence of 200 nM MTX. Fsn0503h cells
were cultured in Dulbeccos Minimum Essential medium
(Invitrogen, Paisley, UK) supplemented with 10% Ultra
Low IgG serum (Invitrogen, Paisley, UK), 1% Penicillin
Streptomycin (PAA laboratories, Austria), and 200 nM
methotrexate (Sigma, Poole, UK). Cells were cultured in
T-flasks (Greiner, GmbH). Cells were routinely passaged
twice a week at ratios between 1:3 and 1:6 according to
the cell density. To express large quantities of antibody-
cells were seeded in T-175 flasks at a seeding density of
3.0-5.0 × 10
4 cells/cm
2 in 30 mL of complete DMEM.
Cells were incubated at 37°C 6% CO2 for 11 days prior to
harvesting of culture medium by centrifugation at 5,000 g
for 40 minutes. Antibody was purified on a protein A col-
umn (GE Healthcare, UK) using AKTA prime chromato-
graphy system (GE Healthcare, UK).
Pharmacokinetic analysis
A PK study was performed to assess the stability and
half-life of Fsn0503h in serum. All animal experiments
were carried out in accordance with the Animal (Scien-
tific Procedures) Act 1986 and conformed to current
UK Co-ordinating Committee on Cancer Research
guidelines. Eight week old male and female Sprague-
Dawley (SD) rats (three male; three female), were
housed in a temperature and humidity-controlled room
for the duration of the study. Blood samples (pre-bleed)
were taken from each animal before treatment with
Fsn0503h. Each animal was administrated with 10 mg/
kg Fsn0503h by intravenous (i.v.) tail injection. Blood
samples (0.5 - 1 mL) were collected in heparinised tubes
at selected time points following administration of
Fsn0503h: 1, 4, 24, 48 hours, then once a week (7, 21,
28, 35, 42 days). Samples were centrifuged following col-
lection, and serum was stored at -20°C until analysis by
ELISA. Briefly, recombinant human cathepsin S was
coated onto a 96-well plate (40 nM) and incubated with
varying dilutions of serum or drug standards for 1 hour
at room temperature. After rinsing with PBS-T second-
ary antibody (rat anti-human horseradish peroxidase-
conjugated antibody) was added to each well. Plates
were incubated for 1 hour at room temperature, washed
with PBS-T and then incubated with TMB for 5 minutes
at room temperature. The reaction was stopped by the
addition of 500 mmol/L HCL, and absorbance was read
at 450 nm.
Cytotoxicity assays
ADCC was determined by conducting a standard Cyto-
Tox 96
® Non-Radioactive Cytotoxicity LDH-Release
Assay purchased from Promega. The LoVo colorectal
cancer cell line and BxPC3 pancreatic cancer cell line
were selected for analysis. The LoVo and BxPC-3 cells
were seeded at 7000 cells/well. Human peripheral blood
mononuclear cells (PBMCs) obtained from healthy
donors were used as effectors cells following IL-2 stimu-
lation (100 U/mL). Both the target (T) and effector (E)
cells were resuspended in 5% FCS RPMI medium with
15 mM HEPES and incubated in triplicate on 96-well
microtiter plates with various concentrations of
Fsn0503h (from 6670 to 833.75 nM) with or without
CD16 neutralizing antibody (6670 nM) at an E:T cell
ratio of 40:1.
Statistical analysis
Statistical analysis was performed on experimental
results using the student t test of variance. All in vitro/
ex vivo experiments were repeated a minimum of three
times and datais expressed as means ± SD.
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